Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.

Authors

Yong Song

Nanjing General Hospital of Nanjing Military Command, Nanjing, China

Yong Song , Yi-Long Wu , Lejie Cao , Jianhua Chen , Zhiyong Ma , Jiuwei Cui , Xin Ye , Jingyan Ding

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).

First Author: Hiroshige Yoshioka

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

First Author: G. Lopes

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).

First Author: Melissa Lynne Johnson

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer.

First Author: Osvaldo Rudy Aren